Dexcom

Qualcomm Sponsoring EvoNexus Incubator Demo Day June 26th, 2023

Retrieved on: 
星期三, 六月 7, 2023
Demo, AMD, InterDigital, Electronics, Y, BD (company), HERE, ResMed, Building, Murata, Bio-Rad Laboratories, SAN, BAE Systems, City National Bank, LG, HP, Cirrus Logic, Semiconductor industry, Cryptocurrency, Mobile phone, Casino, Viasat, Intuit, Dexcom, Qualcomm

SAN DIEGO, June 7, 2023 /PRNewswire/ -- EvoNexus , California's leading non-profit technology incubator, is proud to announce the 2023 EvoNexus Demo Day, sponsored by Qualcomm & Qualcomm Ventures !

Key Points: 
  • SAN DIEGO, June 7, 2023 /PRNewswire/ -- EvoNexus , California's leading non-profit technology incubator, is proud to announce the 2023 EvoNexus Demo Day, sponsored by Qualcomm & Qualcomm Ventures !
  • EvoNexus is also supported by global technology corporate partners that include Qualcomm, Viasat, muRata, pSemi, Becton Dickinson, AMD, HP, LG, Abbott, Royal Bank of Canada, Franklin Templeton, InterDigital, Perma Pure, Intuit, Bio-Rad, BAE Systems, Cirrus Logic, City National Bank, ResMed, EMD Electronics, Dexcom, and more!
  • This year's Demo Day will be held in San Diego at the Qualcomm Irwin M. Jacobs Hall (Building N) on Monday, June 26th, 2023, from 3:30-7PM.
  • For those who do not know what a Demo Day event entails, please view the short video linked HERE

New Wiz Runtime Sensor Pioneers a Unified Approach to Cloud Security

Retrieved on: 
星期一, 六月 5, 2023
Cloud, Noise, Engineering, Risk assessment, CISO, Dexcom, Movement, Organization, Sensor, Workload, Entrepreneurship, Computer security, Medical imaging, Risk management, Video game, Wiz

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Wiz, the leading cloud security platform, today announced the public preview for the Wiz Runtime Sensor, which helps organizations further protect cloud workloads by detecting and responding to potential threats in real-time.

Key Points: 
  • NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Wiz, the leading cloud security platform, today announced the public preview for the Wiz Runtime Sensor, which helps organizations further protect cloud workloads by detecting and responding to potential threats in real-time.
  • By extending its platform with the Wiz Runtime Sensor, Wiz gives organizations a way to do this without having to rely on multiple, fragmented tools.
  • The new Runtime Sensor extends Wiz’s existing agentless visibility with agent-based real-time detection, for the best of both worlds.
  • “The Wiz Runtime Sensor expands Wiz to a ‘defense in depth’ approach, which spans prevention to real-time detection and response.

Dexcom Announces Upcoming Conference Presentation

Retrieved on: 
星期四, 六月 1, 2023
Managed Care, Diabetes, Health Technology, Health, DXCM, Webcast, Dexcom, Conference, Cryptocurrency, Broadcasting

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7th.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7th.
  • The live presentation is scheduled to begin at approximately 1:40 PM EST and will be concurrently webcast.
  • Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.

Know Labs’ Non-Invasive Glucose Monitoring Technology Shows Improved Accuracy

Retrieved on: 
星期二, 五月 30, 2023
Biotechnology, Health Technology, Health, CGM, Blood, Arm, Diabetes, LightGBM, Data collection, Dexcom, Know Labs, Research, MARD, Data, Manuscript, Machine learning, Algorithm, Radio, FDA, NYSE, Data science, Medical device, Cryptocurrency

Know Labs, Inc. (NYSE American: KNW) today announced the results of a new study titled, “ Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs’ Bio-RFID Technology .” The study demonstrates that algorithm optimization using a light gradient-boosting machine (lightGBM) machine learning model improved the accuracy of Know Labs’ Bio-RFID™ sensor technology at quantifying blood glucose, demonstrating an overall Mean Absolute Relative Difference (MARD) of 12.9% – which is within the range of FDA-cleared blood glucose monitoring devices.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW) today announced the results of a new study titled, “ Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs’ Bio-RFID Technology .” The study demonstrates that algorithm optimization using a light gradient-boosting machine (lightGBM) machine learning model improved the accuracy of Know Labs’ Bio-RFID™ sensor technology at quantifying blood glucose, demonstrating an overall Mean Absolute Relative Difference (MARD) of 12.9% – which is within the range of FDA-cleared blood glucose monitoring devices.
  • Like all previous Know Labs clinical studies, this study was designed to assess the ability of the Bio-RFID sensor to non-invasively and continuously quantify blood glucose, using the Dexcom G6® continuous glucose monitor (CGM) as a proxy for the measurement of blood glucose.
  • Unique from previous studies, Know Labs tested new data science techniques and trained a lightGBM model to predict blood glucose using 1,555 observations – or reference device values – from over 130 hours of data collection across five healthy participants.
  • Our whole team is thrilled by these findings and the improved accuracy of our Bio-RFID technology as we continue to refine our approach,” said Ron Erickson, CEO and Chairman at Know Labs.

Granahan Investment Management Marks 30-Year Anniversary of Flagship Small Cap Core Growth Strategy; Outperforms Benchmark, Peers Since Inception

Retrieved on: 
星期四, 五月 25, 2023
Life, Health, Risk management, Salesforce, History, Drew, Russell, Cryptocurrency, Chipotle, Shopify, Dexcom

WALTHAM, Mass., May 25, 2023 /PRNewswire/ -- Granahan Investment Management, LLC., an employee-owned SEC-registered small cap growth equity specialist, recently marked the 30-year anniversary of its flagship strategy, Granahan Small Cap Core Growth, which has outperformed its benchmark and category competitors since inception.

Key Points: 
  • WALTHAM, Mass., May 25, 2023 /PRNewswire/ -- Granahan Investment Management, LLC., an employee-owned SEC-registered small cap growth equity specialist, recently marked the 30-year anniversary of its flagship strategy, Granahan Small Cap Core Growth, which has outperformed its benchmark and category competitors since inception.
  • Granahan Small Cap Core Growth lags the Russell 2000 Growth Index for the one-year period through March 31, 2023.
  • The team-managed strategy ranks as a top quartile performer in the eVestment U.S. small cap growth universe for the five and 10-year periods through March 31, 2023.
  • Granahan Small Cap Core Growth provides strong risk management because it is diversified by sector, LifeCycle category (core growth, pioneer, special situation), and fund manager.

Smart Home Healthcare Revenues Grow to US$26.5 Billion in 2023, Driven by the Remote Monitoring Opportunity

Retrieved on: 
星期三, 五月 17, 2023
CGM, Market data, Research, Building, Social robot, DIY, US, Medtronic, Glucose meter, Growth, Health, Abbott Laboratories, Consumer electronics, Dexcom

NEW YORK, May 17, 2023 /PRNewswire/ -- The smart home healthcare market continues to grow, but the scale of the opportunity remains underpenetrated.

Key Points: 
  • NEW YORK, May 17, 2023 /PRNewswire/ -- The smart home healthcare market continues to grow, but the scale of the opportunity remains underpenetrated.
  • Last year, new smart home healthcare shipment and service revenues grew 25% to reach US$22.9 billion worldwide, but that growth rate will be hard to sustain, despite the considerable potential for further growth.
  • According to global technology intelligence firm ABI Research, new smart home healthcare shipment and service revenues will reach US$26.5 billion in 2023, 15% up from 2022.
  • Smart home healthcare, encompassing connected home care, remote patient monitoring, and social robotics, can improve the health and care of the most vulnerable while reducing manpower and costs.

Smart Home Healthcare Revenues Grow to US$26.5 Billion in 2023, Driven by the Remote Monitoring Opportunity

Retrieved on: 
星期三, 五月 17, 2023
CGM, Market data, Research, Building, Social robot, DIY, US, Medtronic, Glucose meter, Growth, Health, Abbott Laboratories, Consumer electronics, Dexcom

NEW YORK, May 17, 2023 /PRNewswire/ -- The smart home healthcare market continues to grow, but the scale of the opportunity remains underpenetrated.

Key Points: 
  • NEW YORK, May 17, 2023 /PRNewswire/ -- The smart home healthcare market continues to grow, but the scale of the opportunity remains underpenetrated.
  • Last year, new smart home healthcare shipment and service revenues grew 25% to reach US$22.9 billion worldwide, but that growth rate will be hard to sustain, despite the considerable potential for further growth.
  • According to global technology intelligence firm ABI Research, new smart home healthcare shipment and service revenues will reach US$26.5 billion in 2023, 15% up from 2022.
  • Smart home healthcare, encompassing connected home care, remote patient monitoring, and social robotics, can improve the health and care of the most vulnerable while reducing manpower and costs.

DarioHealth Reports First Quarter Financial and Operating Results

Retrieved on: 
星期四, 五月 11, 2023
Well, CGM, ATTD, Partnership, Type 2 diabetes, Pharmacy, Therapy, Digital, Dexcom, GAAP, Research, Ratio, B2C, Back pain, Hospital, Acquisition, International Conference on Afghanistan, London (2006), Amwell, Pharmacy benefit management, Pain management, PBM, Webcast, Sanofi, Depreciation, Growth, Himawari (satellites), Advanced Technology Vehicles Manufacturing Loan Program, Conference, Diabetes, Total, Video game, Retail, Marketing, Pharmaceutical industry, Dario

ET today

Key Points: 
  • ET today
    NEW YORK, May 11, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the first quarter 2023 and provided a corporate and commercial update.
  • "Business-to-Business (B2B) revenues continued to increase, representing approximately 70% of our total revenue during the first quarter, up from 56% in the first quarter of 2022.
  • Total operating expenses excluding stock-based compensation, acquisition expenses, earn-out measurement, and depreciation for the first quarter of 2023 were $10.6 million, compared to $14.8 million for the first quarter of 2022, and $10 million for the fourth quarter of 2022.
  • Operating loss excluding stock-based compensation, acquisition expenses and depreciation for the first quarter of 2023 were $6.3 million compared to $9.9 million for the first quarter of 2022, and $6.0 million for the fourth quarter of 2022.

Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society

Retrieved on: 
星期三, 五月 10, 2023
Wearables, Mobile Technology, Mobile, Wireless, Technology, Medical Devices, Diabetes, Health Technology, Biotechnology, Hardware, Health, Consumer Electronics, CGM, Abstract, Insulin, Rainbow, Metabolism, JDS, Dexcom, Quality of life, Ministry of Health, Labour and Welfare, Research, Rainbow Room, Incidence, G6, Patient, DXCM, Medical device, Pharmaceutical industry, Dietary supplement

DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM System and will highlight the latest clinical evidence that continues to demonstrate the effectiveness of Dexcom CGM during the 66th Annual Meeting of the Japan Diabetes Society held May 11-13, 2023 in Kagoshima, Japan.

Key Points: 
  • DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM System and will highlight the latest clinical evidence that continues to demonstrate the effectiveness of Dexcom CGM during the 66th Annual Meeting of the Japan Diabetes Society held May 11-13, 2023 in Kagoshima, Japan.
  • “As the population of Japan continues to age, the incidence rate of diabetes among older adults is also increasing.
  • To learn more about Dexcom CGM and to get started with Dexcom G6, visit Dexcom.com.
  • Terumo Corporation is the official distributor of Dexcom CGM in Japan.

 Know Labs Study Validates Technical Feasibility of its Novel Sensor for Non-Invasive Glucose Monitoring

Retrieved on: 
星期五, 五月 5, 2023
Hardware, FDA, Other Health, Technology, General Health, Medical Devices, Clinical Trials, Wearables, Mobile Technology, Other Technology, Science, Biotechnology, Other Science, Health, Mobile, Wireless, Research, BGC, NN, Diabetes, Technical report, Informal technical report, AACE, Data collection, Dexcom, Know Labs, Pain, MARD, Data, Clutch (eggs), Radio, NYSE, Food, Software, Medical device, Medical imaging

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of its latest technical feasibility study titled, “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6®.” Know Labs is presenting these results today, May 5, at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle, WA.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the results of its latest technical feasibility study titled, “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6®.” Know Labs is presenting these results today, May 5, at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle, WA.
  • From December 2022 through February 2023, Know Labs conducted a series of internal studies to validate the technical feasibility of its Bio-RFID™ sensor technology at quantifying blood glucose concentration (BGC) in five healthy participants, using the Dexcom G6® as a reference device.
  • Participants' BGC was monitored for three hours while readings from the Bio-RFID sensor and the Dexcom G6® were simultaneously logged.
  • Know Labs then used these data from the Bio-RFID sensor to train a NN model to predict BGC readings of the Dexcom G6® reference device.